Soon, nasal spray for 'better' migraine pain relief

Image
ANI Washington
Last Updated : Nov 07 2014 | 3:10 PM IST

A new research has revealed that scientists are developing a novel prochlorperazine nasal spray formulation for better migraine pain relief.

Migraines are manifested by severe pain and headache that can last anywhere from four to seventy-two hours, accompanied by nausea, vomiting, and sensitivity to both light and sound.

Researcher Venkata Yellepeddi along with his colleagues from Roseman University of Health Sciences developed a preservative-free device-driven prochlorperazine nasal spray that could prove useful for compounding pharmacists specifically in the field of pain medicine.

Yellepeddi said that prochloperazine is a dopamine receptor antagonist that is widely used as an anti-nausea medication and comparative clinical studies have shown that prochloperazine provides better pain relief than other anti-migraine drugs such as sumatriptan, metoclopramide, and ketorolac.

Yellepeddi said that currently, there are no marketed nasal spray formulations of prochlorperazine available for the treatment of migraine and Prochlorperazine is only available in tablet form, which has delayed onset of action.

Researchers hypothesize that a nasal spray version of prochlorperazine will not only be effective, but fast acting and have better patient compliance overall.

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Nov 07 2014 | 2:59 PM IST

Next Story